Actively Recruiting

Age: 8Years +
All Genders
NCT06098430

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Led by St. Jude Children's Research Hospital · Updated on 2026-04-02

100

Participants Needed

7

Research Sites

199 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments. Primary Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with NLPHL. Secondary Objective: * To examine differences in baseline and longitudinal changes in PROs based on disease characteristics, disease status, and treatment strategies among adult and pediatric patients diagnosed with NLPHL.

CONDITIONS

Official Title

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Who Can Participate

Age: 8Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 8 years or older
  • Patient or their adult proxy must have verbal and written English language proficiency
  • Pathologically confirmed diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), including those with transformed lymphoma at or after diagnosis
  • Patient or adult proxy must be able to provide consent
  • Patient and/or adult proxy must be able to complete electronic quality of life surveys
Not Eligible

You will not qualify if you...

  • Age 7 years or younger
  • Patient or adult proxy lacks verbal and written English language proficiency
  • Patients with histologic evidence of a composite lymphoma (NLPHL with concurrent Hodgkin lymphoma, indolent non-Hodgkin lymphoma, or gray zone lymphoma) at diagnosis
  • Inability or unwillingness of participant or legal guardian/representative to provide consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Stanford University Medical Center

Palo Alto, California, United States, 94304

Actively Recruiting

2

University of Colorado Hospital

Aurora, Colorado, United States, 80045

Actively Recruiting

3

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

4

Hackensack University Medical Center

Hackensack, New Jersey, United States, 08837

Actively Recruiting

5

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

6

The University of Rochester Medical Center

Rochester, New York, United States, 14642

Actively Recruiting

7

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Actively Recruiting

Loading map...

Research Team

V

Valerie Crabtree, PhD

CONTACT

J

Jessi Rogers Blake, BSN, RN,CCRP

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here